What is William Blair’s Estimate for Bio-Techne Q4 Earnings?

Bio-Techne Co. (NASDAQ:TECH) – William Blair reduced their Q4 2025 earnings estimates for shares of Bio-Techne in a research note issued on Wednesday, February 5th. William Blair analyst M. Larew now anticipates that the biotechnology company will earn $0.51 per share for the quarter, down from their prior forecast of $0.52. The consensus estimate for Bio-Techne’s current full-year earnings is $1.68 per share. William Blair also issued estimates for Bio-Techne’s Q1 2026 earnings at $0.44 EPS, Q2 2026 earnings at $0.45 EPS, Q3 2026 earnings at $0.56 EPS and Q4 2026 earnings at $0.61 EPS.

Bio-Techne (NASDAQ:TECH) last posted its quarterly earnings data on Wednesday, February 5th. The biotechnology company reported $0.35 EPS for the quarter, missing analysts’ consensus estimates of $0.38 by ($0.03). Bio-Techne had a net margin of 13.22% and a return on equity of 12.73%.

A number of other analysts also recently issued reports on TECH. Robert W. Baird increased their target price on shares of Bio-Techne from $82.00 to $84.00 and gave the stock an “outperform” rating in a research report on Thursday, October 31st. Royal Bank of Canada increased their target price on shares of Bio-Techne from $79.00 to $80.00 and gave the stock a “sector perform” rating in a research report on Thursday, February 6th. StockNews.com raised shares of Bio-Techne from a “hold” rating to a “buy” rating in a research report on Tuesday, November 12th. Scotiabank increased their target price on shares of Bio-Techne from $88.00 to $90.00 and gave the stock a “sector outperform” rating in a research report on Thursday, February 6th. Finally, KeyCorp increased their price objective on shares of Bio-Techne from $80.00 to $90.00 and gave the company an “overweight” rating in a research report on Thursday, February 6th. Two analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, Bio-Techne currently has a consensus rating of “Moderate Buy” and a consensus target price of $86.57.

Bio-Techne Stock Down 4.0 %

TECH opened at $69.92 on Monday. The firm has a 50 day moving average price of $74.44 and a 200 day moving average price of $74.24. The company has a market cap of $11.11 billion, a PE ratio of 70.63, a price-to-earnings-growth ratio of 5.54 and a beta of 1.27. Bio-Techne has a 1 year low of $61.16 and a 1 year high of $85.57. The company has a debt-to-equity ratio of 0.14, a quick ratio of 3.26 and a current ratio of 3.94.

Institutional Investors Weigh In On Bio-Techne

Large investors have recently added to or reduced their stakes in the stock. State Street Corp raised its stake in shares of Bio-Techne by 1.5% during the third quarter. State Street Corp now owns 6,395,993 shares of the biotechnology company’s stock valued at $511,232,000 after purchasing an additional 95,133 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. raised its stake in shares of Bio-Techne by 21.0% during the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,040,840 shares of the biotechnology company’s stock valued at $147,002,000 after purchasing an additional 354,478 shares in the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of Bio-Techne by 3.7% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,465,690 shares of the biotechnology company’s stock valued at $105,574,000 after purchasing an additional 51,687 shares in the last quarter. Point72 Asset Management L.P. bought a new stake in shares of Bio-Techne during the third quarter valued at about $89,724,000. Finally, American Capital Management Inc. raised its stake in shares of Bio-Techne by 2.5% during the third quarter. American Capital Management Inc. now owns 1,114,393 shares of the biotechnology company’s stock valued at $89,073,000 after purchasing an additional 27,508 shares in the last quarter. 98.95% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Bio-Techne news, CEO Kim Kelderman sold 13,392 shares of the stock in a transaction on Monday, January 27th. The stock was sold at an average price of $77.29, for a total value of $1,035,067.68. Following the sale, the chief executive officer now directly owns 39,004 shares of the company’s stock, valued at $3,014,619.16. This trade represents a 25.56 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 3.90% of the stock is currently owned by company insiders.

Bio-Techne Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, February 28th. Stockholders of record on Monday, February 17th will be paid a dividend of $0.08 per share. This represents a $0.32 annualized dividend and a dividend yield of 0.46%. The ex-dividend date of this dividend is Friday, February 14th. Bio-Techne’s dividend payout ratio (DPR) is currently 32.32%.

About Bio-Techne

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.